Indeed, it is rare to see tumour rejection or cure in NSG mice in CAR-T cell studies against solid tumours where mice only receive CAR-T cells with no additional treatment (e.g. checkpoint inhibitors, radiation, IL-2 administration) or where there is no modification of tumour cells. This evidence concerns the gene IL2 and neoplasm.